AcquisitionOther
Revance Therapeutics, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Revance Therapeutics, Inc. -> target · $6.66
The purchase price represents a premium of 89% over Revances closing market price on August 9, 2024, and a 111% premium to Revances 60-day volume-weighted average price.
Open source record (SEC) ↗